Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Other Operating Expenses (2016 - 2023)

CNBX Pharmaceuticals (CNBX) has disclosed Other Operating Expenses for 13 consecutive years, with $11349.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Other Operating Expenses rose 1134800.0% year-over-year to $11349.0, compared with a TTM value of $11349.0 through Feb 2025, changed N/A, and an annual FY2020 reading of $59997.0, down 79.18% over the prior year.
  • Other Operating Expenses was $11349.0 for Q2 2024 at CNBX Pharmaceuticals, up from -$1.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $59997.0 in Q3 2020 and bottomed at -$7551.0 in Q3 2021.
  • Average Other Operating Expenses over 5 years is $10192.1, with a median of $1.0 recorded in 2023.
  • The sharpest move saw Other Operating Expenses tumbled 112.59% in 2021, then surged 1134800.0% in 2024.
  • Year by year, Other Operating Expenses stood at $7551.0 in 2020, then tumbled by 200.0% to -$7551.0 in 2021, then skyrocketed by 99.99% to -$1.0 in 2022, then changed by 0.0% to -$1.0 in 2023, then skyrocketed by 1135000.0% to $11349.0 in 2024.
  • Business Quant data shows Other Operating Expenses for CNBX at $11349.0 in Q2 2024, -$1.0 in Q3 2023, and $1.0 in Q2 2023.